DiagnoCure’s Strategy
Benefiting from molecular biology research, DiagnoCure applies its expertise towards exploring the development of new diagnostic tests for the detection and management of cancer by focusing on such cancers as colorectal, prostate, gastric and breast. In addition to its own research, the Company acquires or in-licenses promising cancer biomarkers from both academic and commercial institutions.
DiagnoCure minimizes time to market in order to introduce innovative diagnostic products, including laboratory developed tests (LDT), analyte specific reagents (ASRs) and in vitro diagnostics (IVDs), to targeted markets.
In order to achieve a leadership position in the promising new market of molecular diagnostics, DiagnoCure focuses on a business model with four imperatives: a focused clinical field (cancer); commercial access to the market; critical mass of proprietary products and favorable access to capital.
Since 2006, DiagnoCure:
- has acquired novel markers for five forms of cancer,
- developed and launched its Previstage™ GCC Colorectal Cancer Staging Test in the U.S. through its own CLIA lab initially; in June 2011, the laboratory was sold to Signal Genetics,
- amended the contract with Gen-Probe with regard to the PCA3 marker for prostate cancer,
- received increasing royalty payments on the PCA3 marker, with the prostate cancer test now being commercialized by Gen-Probe in Europe (over 30 sites), and in the U.S. (in ASR format).
DiagnoCure is well positioned in the market of high-value molecular diagnostic tests for cancer with its PCA3 marker for prostate cancer, its Previstage™ GCC Colorectal Cancer Staging Test, and other promising tests for colorectal, gastric and breast cancers. Depending on the test, target market and geographic area, DiagnoCure will consider working with partners to leverage the commercial potential of its products.